| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| EFFECT | EFFECT |
Other
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| CORRESP | CORRESP |
Other
|
||
| UPLOAD | UPLOAD |
Other
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| S-3 | Simplified registration form |
Registration Statements
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
